drugset / Trial / NCT02268838

Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects

NCT02268838 ↗

Phase 1 Completed 24 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a single-center, placebo-controlled, randomized, ascending dose, double-blind study. This study will be evaluating ascending doses of 50, 100, 200, and 400 mg of E6007. This study consists of 5 steps, 1 to 5. In steps 1 to 4 (at ascending doses of 50, 100, 200, and 400 mg), subjects will be randomly assigned in a 6:2 ratio (E6007: placebo) to receive single dose of the study drug under fasted condition. Following 3 days of washout period, subject will receive the study drug once daily for 7 days starting on the fifth day from the single dose administration. For step 3 (200 mg), subjects will subsequently have at least 17 days of washout period before being escalated to step 5 (200 mg) to receive single dose of E6007 under fed condition, to evaluate food effect of the study drug.

Timeline

Start
2014-10
Primary completion
2015-07
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject E6007 Unknown 50 mg Oral
Subject E6007 Unknown 100 mg Oral
Subject E6007 Unknown 200 mg Oral
Subject E6007 Unknown 400 mg Oral

Indications

No indication recorded.